Effects of treatment with Glucagon‐like peptide‐1 receptor agonist on prediabetes with overweight/obesity: A systematic review and meta‐analysis
Diabetes/Metabolism Research and Reviews · 2023-10 · 39 (7)
DOI: 10.1002/dmrr.3680 ↗At a glance
Metaanalyse in Diabetes/Metabolism Research and Reviews, published online on 2023-06-25. Written by Weihao Wang and 5 co-authors. Institution: Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, …. Major MEDLINE topics: Prediabetic State, Diabetes Mellitus, Type 2. Cited 20 times so far (Crossref); 41 references. Funded by: National Natural Science Foundation of China.
Abstract (original language)
Objective
This study aimed to evaluate the effects of Glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) on prediabetes with overweight/ obesity.
Methods
A search of PubMed, Embase, Cochrane Library, and Web of Science databases was performed to identify randomised controlled trials (up to 4 July 2022) which evaluated the effect of GLP‐1RA on prediabetes with overweight/ obesity.
Results
Eight hundred and nine articles were retrieved (80 from PubMed, 481 from Embase, 137 from Cochrane library, and 111 from Web of Science) and a total of 5 articles were included in this meta‐analysis. More individuals in GLP‐1RAs group regressed from prediabetes to normoglycemia than individuals in the placebo group (OR = 4.56, 95% CI:3.58, 5.80, P = 0.004); fewer individuals in GLP‐1RAs group were diagnosed with diabetes than those in the placebo group (OR = 0.31, 95% CI:0.12,0.81, P = 0.017). Results from five studies showed that GLP‐1RAs significantly reduced fasting glucose (mean difference = −0.41 mmol/L, 95% CI: −0.58, −0.25, P < 0.00001), with an acceptable heterogeneity (I 2 = 42%).
Conclusions
The present meta‐analysis suggested that GLP‐1RA significantly improves glucose metabolism, reduces systolic blood pressure and body weight in prediabetes with overweight/ obesity. It could also prevent the development of diabetes and reverse abnormal glucose metabolism.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
- Peking University Fifth School of Clinical Medicine, Beijing, China.
- School of Biomedical Sciences, University of Queensland, St Lucia, Brisbane, Australia.
ORCID profiles: Weihao Wang
Funding
- National Natural Science Foundation of China
Cite
APA
Wang, W., Wei, R., Huang, Z., Luo, J., Pan, Q., & Guo, L. (2023). Effects of treatment with Glucagon‐like peptide‐1 receptor agonist on prediabetes with overweight/obesity: A systematic review and meta‐analysis. Diabetes/Metabolism Research and Reviews, 39(7). https://doi.org/10.1002/dmrr.3680
Vancouver
Wang W, Wei R, Huang Z, Luo J, Pan Q, Guo L. Effects of treatment with Glucagon‐like peptide‐1 receptor agonist on prediabetes with overweight/obesity: A systematic review and meta‐analysis. Diabetes/Metabolism Research and Reviews. 2023;39(7). doi:10.1002/dmrr.3680
BibTeX
@article{Wang2023,
author = {Wang, Weihao and Wei, Ran and Huang, Zhengxiang and Luo, Jingyi and Pan, Qi and Guo, Lixin},
title = {Effects of treatment with Glucagon‐like peptide‐1 receptor agonist on prediabetes with overweight/obesity: A systematic review and meta‐analysis},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2023},
volume = {39},
number = {7},
doi = {10.1002/dmrr.3680}
}
EUVIMED